Introduction
In the last 15 years, interventional cardiology has been revolutionised by transcatheter aortic valve implantation (TAVI). The initial promise borne out of results from seminal clinical trials has been substantiated by data from numerous real-world registries, and TAVI has become the established treatment for severe, symptomatic aortic stenosis (AS) in patients unable to undergo surgical aortic valve replacement (AVR) due to prohibitive risk. The success of TAVI within this cohort has led to an expansion of its use, and there is now potential for it to be carried out in a wider range of patients such as those with lower surgical risk or with bicuspid aortic valves (BAV). Equally, increased usage and familiarity of the procedure in recent years has enhanced understanding of potential pitfalls and sequelae. This review provides a contemporary perspective on recent developments and controversies relating to TAVI. demonstrated TAVI to be non-inferior to AVR with regard to all-cause mortality and stroke, whilst being associated with a lower propensity for new atrial fibrillation (AF), acute kidney injury (AKI), or major bleeding 6, 7 ( Table 1) . Based on these findings, the ESC guidelines suggest that TAVI may be considered for patients at lower surgical risk after individual evaluation in a multidisciplinary setting. However, whilst these results are ostensibly encouraging, important caveats remain. In both trials, the mean age of patients was >80 years and a significant proportion were considered to be frail. As such, external generalisability may be limited when encompassing younger cohorts. In view of this, and the fact that valve durability beyond 5 years remains largely untested, guidelines continue to favour AVR in patients aged <75 years.
Transcatheter aortic valve implantation in specific circumstances

Concomitant coronary artery disease
It is estimated that 50-75% of patients undergoing TAVI have co-existent coronary artery disease (CAD). 4 Patients undergoing AVR with severe CAD are routinely offered concomitant coronary artery bypass grafting in view of established mortality benefit. However, the optimal management of CAD in patients undergoing TAVI is less well defined as data in the wider literature remain conflicting. For instance, studies have suggested that patients with pre-existing CAD have a higher risk of ischaemic events, major adverse cardiovascular events and mortality. 8, 9 However, registry data have suggested that co-existent CAD is not an independent prognosticator for all-cause mortality, 10 and this was corroborated by a meta-analysis of mid-term outcomes after adjustment for confounders.
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The timing of revascularisation remains equally unclear. Performing percutaneous coronary intervention (PCI) before TAVI in patients with significant CAD appears to be feasible and without associated increase in post-procedural morbidity.
12 Others advocate concomitant PCI to optimise resource utilisation and patient convenience, and results from the Bern TAVI registry indicate that this approach does not confer adverse morbidity and mortality risk. 13 Overall, data for management of co-existent CAD are not robust, and moreover, it remains to be established whether a complete or selective revascularisation strategy should be adopted. In the absence of definitive data, decisions are made on an individualised basis and may vary depending on operator and centre.
Renal impairment
The effects of co-morbid chronic kidney disease (CKD) in those undergoing TAVI have not been extensively investigated as these cohorts are invariably excluded from trials. Nonetheless, smaller prospective studies have demonstrated dialysis-dependant patients to have higher burden of congestive heart failure, in-hospital mortality and short-term mortality post-TAVI compared to those not requiring dialysis. indicated that CKD confers adverse risk in a graded fashion, with those of severe impairment at highest risk. 16 TAVI itself is associated with higher rates of post-procedural AKI than AVR, with an estimated incidence around 12%. 17 Volume of contrast appears to correlate with the development of AKI. 18 Promisingly, an open-label RCT has shown use of the RenalGuard device, with furosemide-induced diuresis and matched isotonic rehydration, to confer significant prophylactic benefit against contrast-induced AKI.
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Small valve annuli
Outcomes of TAVI in the context of small aortic annuli are not well established. A single-centre study of patients with severe AS and annular diameter < 20 mm found reductions in peak transaortic gradients, associated with improvements in exercise capacity and mortality. 20 The incidence of post-procedural aortic regurgitation (AR) was only 2.9%, compared to 12% from the PARTNER 1 trial. 2 This may relate to better apposition of surfaces and minimisation of incongruity with prosthesis. A subsequent study comparing matched cohorts with 20 mm and 23 mm annuli has demonstrated incidence of severe prosthesis-patient mismatch to be similar between groups and low overall.
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Bicuspid aortic valves
Bicuspid aortic valves are a congenital variant that typically result in earlier onset of AS. They exist in approximately 1% of the general population, but in greater than 50% of resected tissue during valve surgery. 22 BAV were previously considered a relative contraindication for TAVI, based on concerns that associated annular dilatation would result in poor seating and subsequent malfunction of the bioprosthesis. 23 However, in recent years, feasibility and efficacy of TAVI in this subgroup have been investigated. Prospective studies comparing BAV and non-BAV have shown comparable success rates and pressure gradients post-deployment. 23 A higher incidence of post-procedure transvalvular AR has been documented, 24 although use of newer-generation devices with an outer fabric skirt does appear to offer some improvement. 25 When compared with tricuspid AS, patients with BAV appear to have similar prognosis post-TAVI, as evidenced by a meta-analysis of pooled outcomes from observational studies. 26 However, recent data suggest higher incidence of conduction disturbance requiring permanent pacemaker (PPM) therapy, with implantation depth and over-sizing of devices potentially attributable. 27 
Severe, pure aortic regurgitation
The use of TAVI for non-calcific severe AR is predominantly untested, and associated with greater anatomical challenges compared with AS. When TAVI devices are deployed in a patient with severe AS, they rely upon the calcific native valve leaflets that are 'crushed' against the aortic wall for fixation. 28 In contrast, the absence of calcification in those with pure AR renders difficulty in anchoring of the device. Pure AR is also associated with aortic root dilatation and may result in a valve annulus that is too large for currently available devices. This itself may result in valve malposition or paravalvular regurgitation. Nevertheless, TAVI for severe, pure AR has been performed successfully in a small cohort, as described in a recent systematic review. 29 Procedural success rates ranged from 74-100% with all-cause mortality at 30 days reported at 7%. Rates of cerebrovascular accidents, major bleeding or vascular complications were encouragingly low, but 9% of patients displayed moderate-severe post-procedural AR. Hence, TAVI in these groups appears to be technically feasible and tolerable but is dependent on further outcome data before it can be viewed as a viable alternative to AVR in routine practice.
Imaging modalities
Severe, symptomatic AS remains the most common indication for TAVI, and transthoracic echocardiography (TTE) is sufficient in the majority of cases to make the diagnosis. However, the co-existence of congestive heart failure with reduced left ventricular ejection fraction (LVEF) and AS can present a diagnostic dilemma. In 5-10% of patients with true severe AS, reduced LVEF is responsible for a 'low-flow, low-gradient' phenomenon, and it can be challenging to distinguish these patients from those with pseudosevere AS, where reduced LVEF results in a reduced opening force on the valve and an underestimation of aortic valve area. 30 The distinction is of clinical significance since patients with pseudosevere AS demonstrate good outcomes with medical therapy, in contrast to those with true severe AS. As such, when assessing the eligibility for TAVI of patients who have AS and reduced LVEF, it is important to identify those in the latter group who may benefit from intervention. Multi-modality imaging with use of low-dose dobutamine stress echocardiography and computed tomography (CT) can aid in differentiating these cohorts. 30 Low-dose dobutamine stress echocardiography enables assessment of aortic valve area in the context of augmented cardiac output, thus differentiating between fixed severe AS and pseudosevere AS, whilst also determining presence of contractile reserve, which has been shown to be of prognostic significance. Meanwhile, CT provides an assessment of aortic valve calcium load, which correlates with aortic valve area. 30 Once patients have been selected for TAVI, detailed further imaging is required. Accurate measurement of the aortic annulus is critically important to determine correct sizing of valve prosthesis, since incorrect sizing may lead to paravalvular leakage, annulus rupture, or valve migration. In general, devices are chosen to be >1 mm larger than the annulus to ensure stable anchoring. Significant variability exists between different imaging modalities, and there is no current gold standard to clarify decision-making. Conventional options such as TTE and two-dimensional transoesophageal echocardiography (TOE) are reliant on a single measurement of diameter and assume a circular geometry. However, annuli are ellipsoid in shape and diameters are therefore typically greater in the coronal compared with sagittal plane. For this reason, many centres advocate three-dimensional (3D) imaging techniques, such as 3D TOE and multi-detector CT (MDCT), to reduce potential for underestimation.
. In comparison with direct surgical sizing pre-AVR, both 3D TOE and MDCT were found to be reliable correlates, though the latter was more effective in the context of pronounced ellipsoid annuli. 31 However, intra-operative sizing is burdened by the caveat that measurements are performed in arrested hearts and subsequent to native valve excision. In patients referred for TAVI, measurements using TTE, TOE and MDCT were correlated but not identical. 32 Consistent with this, a recent meta-analysis has shown that MDCT results in significantly larger diameters, particularly when the coronal plane is utilised. 33 The standard approach for TAVI is in a hybrid operating room with use of general anaesthesia (GA) and TOE. However, there has been recent adoption of a minimalist approach in many centres. This is performed in the catheterisation laboratory with monitored anaesthesia care and use of intracardiac echocardiography. 34 This approach has been shown to reduce resource utilisation and hospitalisation stay with comparable mortality burden. 35 Furthermore, it has been shown to be of benefit in patients with renal dysfunction since it reduces radiocontrast burden. 36 However, conflicting data also exist, with concerns regarding severe paravalvular leak and PPM requirements in those managed without GA. 37 
Access routes
Transfemoral is the most widespread and best evidenced access route for TAVI. 5 Indeed, it was noted in PARTNER 2 that transfemoral TAVI appeared to provide superior outcomes to AVR, although the trial was not adequately powered for this measure. 6 However, approximately 20% of TAVI procedures are not suitable for transfemoral access due to contraindications such as severe vessel calcification, tortuosities and previous vascular procedures, 38 thus necessitating alternative access routes. The transapical approach is the deferral choice for access in many institutions. 39 It is performed under GA and requires an apical puncture secondary to a left anterior mini-thoracotomy. Nonetheless, the antegrade implantation route allows precise valve positioning and deployment, and permits use of larger calibre sheaths. Ten-year institutional data suggest long-term preservation of valve anatomy and function, as well as low incidence of neurological complications, which may relate to reduced manipulation in the aortic arch during valve delivery and deployment. 40 However, these benefits ought to be balanced with certain reservations. The STACCATO trial, a comparison between transapical TAVI and AVR in elderly patients eligible for surgery, was halted prematurely due to increased adverse events in the TAVI group. 41 Furthermore, there are concerns regarding increased rates of non-cardiovascular mortality, potentially attributable to inherent risks of myocardial injury and respiratory failure. 42 A direct transaortic approach is emerging as the second-or third-line choice in centres of high experience. Drawbacks include the need for GA and an upper mini-sternotomy, and it is technically challenging in those with a history of previous coronary artery bypass grafting or severe respiratory disease. 39 However, it has the advantage of avoiding direct myocardial injury. Subclavian or transaxillary access appears to be technically feasible, and a multicentre study has shown equivalent success rate and 12-month efficacy to the transaortic route. 43 A left-sided approach is preferred due to a favourable implantation angle, although caution is warranted in patients with patent left internal mammary artery grafts or left-sided pacemaker devices.
In those with unfeasible access through one of the above strategies, bail-out options include transcarotid and caval-aortic approaches. A systematic review on the transcarotid approach has shown comparable outcomes to other access routes, though sample size was small with heterogeneous endpoints. 44 It can be undertaken under local anaesthesia or GA, though there was higher incidence of peri-operative strokes noted in the latter. 45 The caval-aortic approach involves retrograde access at the infra-renal level, which incorporates benefits of both venous and arterial access without the requirement for a trans-septal puncture. 46 Insertion of catheter sheaths into distensible veins may help mitigate arterial access site complications, whilst formation of caval-aortic fistulae appears to be tolerable and easily remedied with closure devices. No prospective data on clinical outcomes are available, but it is conceivable that this approach may be suitable in a subgroup of patients where no other formal means of access is achievable.
Overall, outcome data for access routes in TAVI are based predominantly on observational studies. Until definitive evidence is published, current practice is to use an individualised approach based upon arterial anatomy, existence of co-morbidities, and expressed preference of both clinician and patient.
Selection of prosthesis
The original TAVI prostheses used in the PARTNER and US CoreValve trials were Edwards SAPIEN and Medtronic CoreValve devices, respectively. These differ fundamentally in the method by which they are deployed, with the Edwards SAPIEN being balloon-expandable and the Medtronic CoreValve being self-expandable. This disparity imbues differing characteristics, notably with regard to propensity for sequelae such as conduction disturbance and aortic root rupture.
Further exploration of differences between these two valve types was provided by the CHOICE trial with a head-to-head RCT comparison. 47 Implantation of the Edwards SAPIEN device was associated with higher success rates, lower frequency of residual AR and lower requirement for pacemaker implantation. However, the self-expandable Medtronic CoreValve resulted in lower mean transvalvular gradients and a trend towards lesser strokes and coronary artery occlusions. Significantly, the trial demonstrated no overall difference between the two prosthesis subtypes with respect to 30-day and 1-year mortality.
There has been a recent expansion in the devices available, with newer types providing a number of significant advantages over their antecedents, including the ability to be repositioned following deployment, reduced rate of paravalvular AR, and delivery via smaller vascular sheaths. Currently, there are no RCTs available to provide direct comparisons.
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Procedural complications and sequelae
Cardiac tamponade
Cardiac tamponade is a recognised complication for all percutaneous cardiac procedures, and existing literature describes occurrence in up to 4% of TAVI cases. 48 Theoretical risk is highest at the time of positioning of a temporary pacing lead within the right ventricle, positioning of a stiff guidewire in the left ventricle, and deployment of the device itself. Use of a temporary pacing lead is routine during TAVI, as it enables rapid pacing which precipitates transient ventricular standstill and facilitates valve positioning and deployment. However, its use carries a small risk of ventricular perforation. Use of flow-directed systems with an inflatable balloon at the tip of the pacing lead reduces this risk but does not ameliorate it. A clinical trial is planning to assess feasibility of using the valve delivery guidewire itself to rapidly pace the left ventricle, thus obviating need for a right ventricular lead altogether. 49 Tamponade is also possible at the time of device deployment, in the event of aortic root rupture. Predictive factors include use of balloon-expandable prostheses in patients with calcified left ventricular outflow tracts (LVOT), particularly when the device is aggressively oversized. 48 Aortic root rupture is less frequently observed when self-expandable prostheses are used. As such, use of pre-procedural CT scanning followed by selection of a self-expandable device in patients noted to have a heavily calcified LVOT is a potential strategy to mitigate risk.
Cerebrovascular events
These may occur in the intra-or post-procedural phase, and portend poor outcomes with a three-to nine-fold increase in mortality. 50 Whilst recent studies have shown reduced incidence when compared to initial trials, 51 neurological sequelae post-TAVI remain concerning. Use of diffusion-weighted magnetic resonance imaging (DW-MRI) has shown that ischaemic brain lesions can be detected in 68-100% of patients post-procedure. 50 In view of this, extensive research into embolic protection devices (EPD) during TAVI has been conducted. DEFLECT III was an exploratory study that reported reductions in a number of DW-MRI-related endpoints in EPD-treated patients, 50 and the subsequent SENTINEL trial showed numerical reductions in DW-MRI detected new cerebral lesions and total number of strokes at 30 days. 52 Notably however, none of these findings reached statistical significance. Encouragingly, the CLEAN-TAVI trial has demonstrated significant reductions in the number and volume of cerebral lesions. 53 In spite of promising trial data, there remains doubt regarding the benefit of EPDs. It is notable that no study of EPDs has yet demonstrated a significant reduction in the occurrence of overt strokes. Furthermore, use of DW-MRI-related endpoints is contentious since clinical relevance of such lesions remains uncertain. Although studies undertaken in other clinical settings have linked such 'silent' events to cognitive decline and development of vascular dementia, 54 this is not proven in the context of TAVI. Indeed, one study that assessed the temporal characteristics of DW-MRI-identified intracranial lesions post-TAVI showed 100% resolution after 6 months. 55 Hence, the evidence for routine use of EPDs during TAVI appears equivocal at best. However, there may be rationale in selective use of EPDs for patients at high risk of peri-procedural stroke (for example, those with prior stroke or a heavily calcified aortic arch), and certain institutions implement this policy.
Conduction defects requiring pacemaker implantation
This is a relatively common complication following TAVI, with a documented rate of 17% in a recent meta-analysis, and the most frequent indication being complete heart block. 56 Device expansion within the annulus may cause extrinsic compression of the atrioventricular node and bundle branch fibres due to close anatomical proximity. Predictive factors can be grouped into patient characteristics or technical factors relating to the procedure; the former includes male sex and pre-existing conduction disease (including left anterior hemiblock, right bundle branch block, and first degree block), whilst the latter includes use of self-expandable prostheses and intra-procedural atrioventricular block. 56 Self-expandable prostheses have higher rates of conduction disease than their balloon-expandable counterparts, which may be due in part to their longer dimensions which necessitate deeper implantation into the LVOT. Prosthesis-to-LVOT diameter ratio and left ventricular end-diastolic diameter have been shown as additional predictors in a subgroup analysis of the PARTNER 1 trial. 57 It also found that PPM implantation post-TAVI correlated with longer duration of hospitalisation and higher risk of recurrent admissions within 12 months.
Obstruction of coronary ostia
This is a complication that may arise either as a result of device malposition or displacement of native leaflets. Close proximity of the ostia to the valve annulus, bulky calcification of either the right or left valve leaflets, and a narrow sinus of Valsalva are the most significant predictive factors, and can usually be identified via imaging with MDCT. 58 In cases where pre-procedural imaging demonstrates risk of ostial occlusion, pre-implant balloon valvuloplasty with simultaneous aortography can be used to assess for coronary artery patency during balloon inflation. If this demonstrates compromised flow, pre-emptive wiring of the vessels can be performed to enable prompt PCI if needed. If coronary obstruction is noted following TAVI deployment and PCI is unable to restore coronary patency, the prosthesis should either be snared and removed or retracted into the ascending aorta via use of an oversized balloon. 3-6 month regimen succeeded by lifelong treatment with single antiplatelet therapy (SAPT). 5 However, evidence supporting this strategy is rather scarce and the rationale for using DAPT is a direct extrapolation of data from PCI trials. 59 As more observational data have been generated, there has been a broad intent to reduce intensity and duration of antiplatelet regimen to minimise bleeding sequelae. Patients in the PARTNER 1 trials were maintained on DAPT for 6 months post-procedure, 1,2 whereas the duration was reduced to 1 month in PARTNER 2. 6 Indeed, some centres have ceased implementation of post-procedural DAPT altogether, instead maintaining patients on aspirin monotherapy. Recent literature appears to support this approach. A prospective, non-randomised study comparing SAPT to DAPT following TAVI showed no significant differences in incidence of myocardial infarction or stroke, but a significant reduction in major bleeding with SAPT. 60 Furthermore, a systematic review comparing aspirin to DAPT post-TAVI has published comparable results. 61 A RCT directly comparing these two strategies is currently ongoing, and is expected to provide the most definitive evidence to date. 62 Whilst there is a trend towards reduction in use of antiplatelets, there is evidence to support a short period of oral anticoagulation (OAC) post-procedure. Systematic follow-up using CT scanning has revealed the presence of partial thrombosis of at least one cusp in 10-15% of cases. 59 Through assessment of hypo-attenuated leaflet thickening, this phenomenon appears independent of the antiplatelet regimen used, but significantly, it demonstrates reversibility with anticoagulation. 63 However, the benefit of OAC on hard outcome measures remains to be clarified and as such, routine anticoagulation of patients in sinus rhythm following TAVI is rarely practised.
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Antiplatelet and anticoagulant therapy
A quarter of patients who undergo TAVI have AF, and in these instances, OAC is a necessity. Identifying the optimal regimen of antiplatelet and anticoagulant therapy has evident challenges, and there remains a paucity of evidence in this area. A non-randomised trial comparing OAC alone to SAPT or DAPT plus OAC for patients in AF that have undergone TAVI displayed no significant differences with respect to stroke, major adverse cardiovascular events, or mortality. 64 However, there was increased occurrence of major bleeding amongst those treated with SAPT/DAPT and OAC. Currently, the exact regimen utilised requires an individualised approach which is dependent on operator, institution and patient profile.
Conclusions
Transcatheter aortic valve implantation has become established as an effective interventional strategy for severe AS in those at high surgical risk. A combination of increased procedural familiarity and progression in device technology has enabled improvements to be made in complication rates, morbidity and mortality. This has led to a commensurate expansion in the use of TAVI, including in patients at lower surgical risk, as well as in specific subgroups such as those with BAV and small annuli, where results are preliminary but encouraging. However, there remain areas of uncertainty, such as management of concomitant CAD, use of EPDs and post-procedural anti-thrombotic regimen. A lack of conclusive evidence relating to these issues can present challenges in the decision-making process. Ongoing and upcoming large-scale clinical trials are anticipated to provide more definitive evidence, and may herald the emergence of a new era in the field of TAVI. Conflict of interest: none declared.
